Evidence map›Paper›PMID 37624552›Full record

ArticleBreast cancer research and treatment2023

Impact of age, race, and family history on COVID-19-related changes in breast cancer screening among the Boston mammography cohort study.

Naiyu Chen, David Cheng, Michelle O Sodipo, Mollie E Barnard, Natalie C DuPre, Rulla M Tamimi, Erica T Warner

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Naiyu ChenDepartment of Epidemiology, Harvard T.H Chan School of Public Health, Boston, MA, USA.
David ChengBiostatistics Center, Massachusetts General Hospital, Boston, MA, USA.
Michelle O SodipoDepartment of Epidemiology, Harvard T.H Chan School of Public Health, Boston, MA, USA.
Mollie E BarnardDepartment of Population Health Sciences, Huntsman Cancer Institute, University of Utah Intermountain Health, Salt Lake City, UT, USA.
Natalie C DuPreDepartment of Epidemiology and Population Health, School of Public Health and Information Sciences, University of Louisville, Louisville, KY, USA.
Rulla M TamimiDepartment of Population Health Sciences, Weill Cornell Medical, New York, NY, USA.
Erica T WarnerClinical Translational Epidemiology Unit, Department of Medicine, Mongan Institute, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA. ewarner@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-2671-0313

Funding

Translational Research Support CoreP30ES000002 · NIEHS · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI Marc G Weisskopf · 1985 to 2026
$44.6M
Training Program in Cancer EpidemiologyT32CA009001 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI A. Heather Eliassen, Meir Stampfer · 1985 to 2026
$17.3M
University of Louisville Center for Integrative Environmental Health SciencesP30ES030283 · NIEHS · UNIVERSITY OF LOUISVILLE · PI Amanda Jo LeBlanc · 2020 to 2026
$10.0M
Race/Ethnicity and Mammographic Density: Genetic and Lifestyle FactorsK01CA188075 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI WARNER, ERICA T · 2014 to 2017
$518k
Inflammation and gynecologic cancer: the role of prostaglandins in ovarian cancerK00CA212222 · NCI · UNIVERSITY OF UTAH · PI BARNARD, MOLLIE ELYSE · 2018 to 2021
$415k
Inflammation and gynecologic cancer: the role of prostaglandins in ovarian cancerF99CA212222 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI BARNARD, MOLLIE ELYSE · 2016 to 2017
$64k
NCI NIH HHS F99 CA212222NCI NIH HHS K00 CA212222NCI NIH HHS K01 CA188075NCI NIH HHS K01CA188075NCI NIH HHS T32 CA009001NCI NIH HHS T32CA09001NIEHS NIH HHS P30 ES000002NIEHS NIH HHS P30 ES030283
6 · The paper itself

Abstract

purposeWe studied women enrolled in the Boston Mammography Cohort Study to investigate whether subgroups defined by age, race, or family history of breast cancer experienced differences in the incidence of screening or diagnostic imaging rates during the COVID-19 lockdown and had slower rebound in the incidence of these rates during reopening.

methodsWe compared the incidence of monthly breast cancer screening and diagnostic imaging rates over during the pre-COVID-19 (January 2019-February 2020), lockdown (March-May 2020), and reopening periods (June-December 2020), and tested for differences in the monthly incidence within the same period by age (< 50 vs ≥ 50), race (White vs non-White), and first-degree family history of breast cancer (yes vs no).

resultsOverall, we observed a decline in breast cancer screening and diagnostic imaging rates over the three time periods (pre-COVID-19, lockdown, and reopening). The monthly incidence of breast cancer screening rates for women age ≥ 50 was 5% higher (p = 0.005) in the pre-COVID-19 period (January 2019-February 2020) but was 19% lower in the reopening phase (June-December 2020) than that of women aged < 50 (p < 0.001). White participants had 36% higher monthly incidence of breast cancer diagnostic imaging rates than non-White participants (p = 0.018).

conclusionThe rebound in screening was lower in women age ≥ 50 and lower in non-White women for diagnostic imaging. Careful attention must be paid as the COVID-19 recovery continues to ensure equitable resumption of care.

Indexed as

Breast NeoplasmsCOVID-19BostonCohort StudiesCommunicable Disease ControlEarly Detection of CancerFemaleHumansMammographyBreast cancerCOVID-19Diagnostic imagingEpidemiologyScreening

Identifiers

PMID37624552
PMCPMC11265187

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.